National context
In the sector of pharmaceutical product development, Italy plays an entirely marginal role vis-à-vis the rest of Europe and many other countries worldwide.
In our country, the transition from basic to applied research is very weak: though Italy is an excellent pharmaceutical market in terms of value, revenues from sales are reinvested in other countries.
By offering high-quality services, Fase 1 intends to:
- bring the new potential diagnostic agents generated by Italian research to a more advanced stage of preclinical and clinical development
- attract phase I and II clinical trials to Sardinia
- enhance the innovation capabilities of Sardinia’s health system.
In our country, the transition from basic to applied research is very weak: though Italy is an excellent pharmaceutical market in terms of value, revenues from sales are reinvested in other countries.
By offering high-quality services, Fase 1 intends to:
- bring the new potential diagnostic agents generated by Italian research to a more advanced stage of preclinical and clinical development
- attract phase I and II clinical trials to Sardinia
- enhance the innovation capabilities of Sardinia’s health system.
